FOR PATIENTS
Clinical Trials

OTHER SOLID TUMORS
(LUMINOS-103)

A basket trial of lerapolturev (formerly PVSRIPO) and lerapolturev in combination with anti–PD-1/L1 checkpoint inhibitors in multiple solid tumor types

A basket trial of lerapolturev (formerly PVSRIPO) and lerapolturev in combination with anti–PD-1/L1 checkpoint inhibitors in multiple solid tumor types

LUMINOS-103 Study Design

Study design of LUMINOS-103
  1. DLT, dose-limiting toxicity; DSMC, Data Safety Monitoring Committee; HNSCC, head and neck squamous cell cancer; MIBC, muscle-invasive bladder cancer.

LUMINOS-103 Study Design

Study design of LUMINOS-103
  1. DLT, dose-limiting toxicity; DSMC, Data Safety Monitoring Committee; HNSCC, head and neck squamous cell cancer; MIBC, muscle-invasive bladder cancer.

LUMINOS-103 (NCT04690699) is a multicenter, open-label, single-arm phase 1/2 basket study investigating the efficacy and safety of lerapolturev in several solid tumor types. The study enrolled its first patient in October 2021 and is ongoing at a rapidly expanding list of US sites.

Cohort
Tumor type
Setting
A
MIBC
Neoadjuvant treatment of patients with MIBC who refuse or are ineligible for cisplatin
B
MIBC
First-line treatment of unresectable or metastatic MIBC
C
HNSCC
Neoadjuvant treatment of patients with resectable, locally advanced HNSCC
D
HNSCC
First-line treatment of unresectable or metastatic HNSCC

The phase 1 part of each study will include approximately 6 patients with each tumor type, who will be evaluated for safety. Once approved by the DSMC, the phase 2 part of the study will enroll approximately 25 patients in each cohort.

Get additional information

Please contact us or email LUMINOS-103@istarioncology.com.

*Required.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.